935667-36-0

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
N5,N5-dimethyl-1H-pyrazole-3,5-diamine is used as a building block for the synthesis of various pharmaceuticals and agrochemicals. Its unique structure allows for the development of new compounds with potential therapeutic and pesticidal properties.
Used in Organic Chemical Reactions:
N5,N5-dimethyl-1H-pyrazole-3,5-diamine serves as a reagent in organic chemical reactions, facilitating the synthesis of complex organic molecules and contributing to the advancement of organic chemistry.
Used in Specialty Polymers and Resins Production:
N5,N5-dimethyl-1H-pyrazole-3,5-diamine is utilized as a component in the production of specialty polymers and resins, enhancing their properties and expanding their applications in various industries.
Safety and Handling:
Due to its chemical properties and potential hazards, N5,N5-dimethyl-1H-pyrazole-3,5-diamine should be handled and stored according to relevant safety guidelines and regulations to ensure the safety of workers and the environment.

Upstream product

• 178483-39-1 (2Z)-3-(dimethylamino)-3-(methylthio)acrylonitrile 
• 935667-35-9 3-(dimethylamino)-3-(methylthio)acrylonitrile 

Relevant academic research and scientific papers

Discovery of 5-chloro- N 2-[(1 S)-1-(5-fluoropyrimidin-2-yl) ethyl]- N 4-(5-methyl-1 H -pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the jak/stat pathway

The myeloproliferative neoplasms, polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis are a heterogeneous but related group of hematological malignancies characterized by clonal expansion of one or more myeloid lineages. The discovery of the Jak2 V617F gain of function mutation highlighted Jak2 as a potential therapeutic target in the MPNs. Herein, we disclose the discovery of a series of pyrazol-3-yl pyrimidin-4-amines and the identification of 9e (AZD1480) as a potent Jak2 inhibitor. 9e inhibits signaling and proliferation of Jak2 V617F cell lines in vitro, demonstrates in vivo efficacy in a TEL-Jak2 model, has excellent physical properties and preclinical pharmacokinetics, and is currently being evaluated in Phase I clinical trials.

4- (3-AMINOPYRAZOLE) PYRIMIDINE DERIVATIVES FOR USE AS TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CANCER

This invention relates to novel compounds having the formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.

PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSYNE KINASES

Compounds of formula (I): and their use in the inhibition of Trk activity are described.